SVB Securities analyst Roanna Ruiz reiterated a Buy rating on ARS Pharmaceuticals (SPRY – Research Report) on June 20 and set a price target of $13.00. The company’s shares closed yesterday at $6.35.
According to TipRanks, Ruiz is an analyst with an average return of -8.7% and a 41.98% success rate. Ruiz covers the Healthcare sector, focusing on stocks such as ARS Pharmaceuticals, Lantheus, and scPharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for ARS Pharmaceuticals with a $14.00 average price target, which is a 120.47% upside from current levels. In a report released yesterday, Wedbush also reiterated a Buy rating on the stock with a $15.00 price target.
See today’s best-performing stocks on TipRanks >>
SPRY market cap is currently $601.8M and has a P/E ratio of -2.62.
Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SPRY in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Silverback Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on leveraging its ImmunoTAC technology platform to develop tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases.
Read More on SPRY:
- ARS Pharmaceuticals announces PDUFA date extension for neffy
- ARS Pharmaceuticals Highlights Progress and Reports First Quarter 2023 Financial Results
- FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for neffy® (Intranasal (IN) Epinephrine) for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis
- ARS Pharmaceuticals Announces Availability of Briefing Documents for FDA Advisory Committee Meeting on neffy® for the Treatment of Type I Allergic Reactions Including Anaphylaxis
